Table 2.
Antibody titers in participants with suspected breakthrough SARS-CoV-2 infection.
| Age (years) | Sex |
Antibody titer 3 months after vaccination |
Antibody titer 6 months after vaccination |
History of possible SARS-CoV-2 infection 3 to 6 months after vaccinationa |
|||||
|---|---|---|---|---|---|---|---|---|---|
|
STACIA Neut-Ab, U/mL |
N-IgG, SU/mL |
STACIA Neut-Ab, U/mL |
N-IgG, SU/mL | COVID-19 | COVID-19-like illness | SARS-CoV-2 PCR testing | Close contact with COVID-19 patients | ||
| 44 | F | 6.45 | 0.5 | 51.38 | 19.8 | − | − | − | − |
| 27 | F | 9.86 | 0.1 | 52.92 | 22.3 | − | − | + | − |
| 47 | F | 10.73 | 0 | 42.21 | 79.9 | − | − | − | − |
| 31 | F | 9.92 | 5.4 | 20.55 | 173.3 | − | − | − | − |
| 50 | F | 7.68 | 0.1 | 53.73 | 55.3 | + | + | + | + |
| 45 | F | 5.17 | 0.1 | 53.24 | 83.0 | − | − | + | + |
COVID-19, coronavirus disease; N-IgG, immunoglobulin G antibody against the SARS-CoV-2 nucleocapsid antigen; Neut-Ab, neutralization antibody test; PCR, polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2
a
Based on answers provided in the questionnaire.